The Russian drug for the first time entered the program of accelerated registration in Europe
For the first time in the PRIME program of the European Medicines Agency (EMA), intended for the accelerated registration of innovative drugs, a Russian development was included - a tool for the treatment of Hepatitis B Myrcludex B from Hepater, according to the website...
June 01, 2017